Tempus AI

Tempus AI EBIT Growth

The Year-over-Year EBIT Growth of Tempus AI (TEM) as of Nov 14, 2026 is 63.41 %. In the previous year, Year-over-Year EBIT Growth was -252.44 % — a change of -125.12% (higher).

EBIT Growth

63.41 %

YoY

-125.12%

Last updated:

Year-over-Year EBIT Growth of Tempus AI is 2025 63.41 % . Year-over-Year EBIT Growth of Tempus AI was 2024 -252.44 % . It decreases by -125.12% higher compared to the previous year.

The Tempus AI EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2020
-61.51 USD
Jan 1, 2021
-25.98 USD
Jan 1, 2022
-8.92 USD
Jan 1, 2023
26.13 USD
Jan 1, 2024
-252.44 USD
Jan 1, 2025
63.41 USD
The Tempus AI EBIT Growth history
YEAREBIT GrowthYoY
63.41 %-125.12%
-252.44 %-1,066.12%
26.13 %-393.04%
-8.92 %-65.68%
-25.98 %-57.76%
-61.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Year-over-Year EBIT Growth of Tempus AI is 63.41 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Tempus AI since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Tempus AI

All Key Metrics — Tempus AI